AxoGen (AXGN) Corporate presentation summary

Mission and market opportunity

• Focused on making peripheral nerve repair an expected standard of care to restore health and improve quality of life.

• Targets a $5.6B US nerve care market with over 1.5 million treatable injuries annually across extremities, breast reconstruction, oral/maxillofacial, and prostate surgery.

• Nerve injuries significantly impact patient quality of life, with high incidence in trauma, surgery, and amputation cases.

Product portfolio and innovation

• Avance is the only FDA-approved biologic nerve scaffold for peripheral nerve discontinuities, supported by proprietary quality assays.

• Comprehensive portfolio includes Avance, Axoguard, and Avive+ products, covering connection, protection, and termination in nerve repair.

• Ongoing innovation with new product development and clinical applications, including prostate and breast neurotization.

Market development and education

• Key barriers include lack of standardized care guidelines, low awareness, inefficient referral pathways, and partial insurance coverage.

• Strategic plan prioritizes 15-20% CAGR, commercial expansion, clinical evidence generation, and product innovation.

• Extensive education and training initiatives, with 75% of hand fellows and 1,400 surgeons trained on nerve repair algorithms.